SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer ...

The Urology Care Foundation and the Prostate Cancer Foundation have created a new educational guide on genetic tests to guide ...

SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic and tumor genomic testing, commends the updated Prostate Cancer Guidelines from the ...

Scientists at EPFL and Johns Hopkins uncover the central role of an enzyme in controlling prostate cancer subtypes and ...

A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...

Early testing is key to addressing the rise in cases of prostate cancer in Africa - and it doesn't have to be an invasive procedure. That's the message from cancer survivors and health experts on the ...

MOBILE, Ala. (WKRG) — According to the National Cancer Institute, up to 60% of the risks of prostate cancer are caused by inherited genes. Amanda Trulock, MS, CGC, from USA Health joined WKRG to ...

Myriad Genetics, Inc. has announced a strategic collaboration with PATHOMIQ, Inc., which allows Myriad to exclusively license PATHOMIQ_PRAD, an AI technology platform for prostate cancer diagnostics ...

Genetic screening for prostate cancer can help identify inherited risks early, guide treatment decisions, and protect your family’s health. At Fred Hutch Cancer Center, we offer expert genetic ...